- Poster presentation
- Open Access
HIV-1 dual infection is associated with faster CD4+T cell decline in a cohort of men with primary HIV infection
© Cornelissen et al; licensee BioMed Central Ltd. 2011
- Published: 3 October 2011
- Primary Infection
- Early Start
- Dual Infection
- Coreceptor Usage
- Clinical Disease Progression
In vitro, animal and mathematical models suggest that HIV co-or superinfection would result in increased fitness of the pathogen, and possibly associated increased virulence. However, in patients the impact of HIV-1 dual infection on disease progression is unclear, because parameters relevant for disease progression have not been strictly analysed. The objective of the present study is to analyse the effect of HIV-1 dual infections on disease progression in a well-defined cohort of men having sex with men [MSM).
Between 2000 and 2009 37 primary HIV-1, subtype B infected men, with no immediate indication for combination antiretroviral therapy (cART), and sufficient follow-up were characterized with regard to single- or dual infection, HLA-I type, CCR5 genotype and coreceptor usage. Patients were followed to estimate the effect of these parameters on clinical disease progression, as defined by the rate of CD4+T-cell decline and start of cART.
Four patients presented with an HIV-1 coinfection, six patients acquired an HIV-1 superinfection, on average 8.5 months from their primary infection, and twenty-seven patients remained single infected. Longitudinal CD4+ T-cell slopes and time-weighed changes from baseline were significantly steeper in dual- as compared to single-infected patients. Multivariate analysis showed that the most important parameter associated with CD4+T-cell decline over time was dual infection (p=0.001). Additionally, patients with an HIV-1 coinfection had a significantly earlier start of cART (p<0.0001).
HIV-1 dual infection is the main factor associated with CD4+ T-cell decline in untreated, primary HIV-1, subtype B infected men.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.